In vitro: 666-15 potently inhibits cancer cell growth. In MDA-MB-231 and MDA-MB-468 cells, the GI50 for 666-15 is 73 and 46 nM, respectively. In A549 and MCF-7 cells, it exhibits robust activity as well with GI50 of 0.47 and 0.31 μM. 666-15 is also found to be a rather weak inhibitor of CREB-CBP interaction with IC50 of 18.27 μM. 666-15 inhibits CREB’s transcription activity in living cells independent of direct CREB or CBP binding interaction. 666-15 is very potent in inhibiting CREB’s transcription activity. 666-15 also inhibits endogenous CREB target gene expression, the transcript level of nuclear receptor related 1 protein (Nurr1/NR4A2). In vivo: Preliminary toxicity studies show that intraperitoneal (ip) injection of 10 mg/kg of 666-15 is well tolerated in mice. The tumor growth in the mice treated with 666-15 is efficaciously inhibited with complete tumor stasis. During the same period, the tumor volume in the vehicle-treated group is more than tripled. The body weights of 666-15-treated animals and vehicle-treated ones are indistinguishable from each other during the entire treatment period.
Bone Joint Res. 2024 Jan;2;13(1):4-18.
The CREB1 inhibitor 666-15 maintains cartilage homeostasis and mitigates osteoarthritis progression
666-15 purchased from AbMole
Neurourol Urodyn. 2020 Apr 24.
β-Adrenoceptors Regulate Matrix Metalloproteinase Expression in Human Urothelial Cells Under Hydrostatic Pressure.
666-15 purchased from AbMole
Life Sci. 2019 Dec 1;238:116979.
Effects of progesterone on glucose uptake in neurons of Alzheimer's disease animals and cell models.
666-15 purchased from AbMole
Cell Experiment | |
---|---|
Cell lines | MDA-MB-231 and MDA-MB-468 cells |
Preparation method | Cells are plated into 96-well plates and the cells are allowed to attach to the bottom of the plates overnight. Then the cells are treated with different concentrations of different drugs (666-15) for 72 h. The media are removed, and MTT reagent in complete tissue culture media is added to each well and incubated at 37 °C for 3 h. The incubation media are removed and 100 μL of DMSO is added to each well. The absorbance of the formed purple formazan solution is read at 570 nm using a plate reader. |
Concentrations | 80 nM |
Incubation time | 72 h. |
Animal Experiment | |
---|---|
Animal models | BALB/c nude mouse |
Formulation | 1% N-methylpyrrolidone (NMP), 5% Tween-80 in water |
Dosages | 10 mg/kg |
Administration | i.v. |
Molecular Weight | 620.52 |
Formula | C33H31Cl2N3O5 |
CAS Number | 1433286-70-4 |
Solubility (25°C) | 30 mg/mL in DMSO |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related Epigenetic Reader Domain Products |
---|
Phoenixin-20
Phoenixin-20 (PNX-20) is a bioactive peptide with hormone-like actions in vertebrates, and can stimulates hypothalamo-pituitary-gonadal hormones and regulate reproductive processes in mammals. |
Menin-MLL inhibitor 31
Menin-MLL inhibitor 31 is a potent inhibitor of the menin MLL interaction with an IC50 value of 4.6 nM. |
OPN-2853
OPN-2853 is a bromodomain protein-4 (BRD4) inhibitor that can be used in studies related to hematologic and lymphatic disorders. |
HDAC/JAK/BRD4-IN-1
HDAC/JAK/BRD4-IN-1 is a potent HDAC/JAK/BRD4 triple inhibitor. |
VYN-201
VYN-201 is a novel pan-BET inhibitor for studies related to idiopathic pulmonary fibrosis. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.